Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.

REGN vs. RGEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

REGN vs. RGEN: Which Stock Is the Better Value Option?

Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

by Zacks Equity Research

Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth

by Zacks Equity Research

Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.

If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates

by Zacks Equity Research

Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

by Zacks Equity Research

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

by Zacks Equity Research

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity.

Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GSEW

AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe

by Zacks Equity Research

AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

by Zacks Equity Research

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

by Zacks Equity Research

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

by Zacks Equity Research

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Company News for Sep 9, 2022

by Zacks Equity Research

Companies in The News Are: REGN, JPM, CASY, GME

Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success

by Zacks Equity Research

Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

by Zacks Equity Research

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPGP

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

by Zacks Equity Research

Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.

Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab

by Zacks Equity Research

Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.

Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

by Zacks Equity Research

Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.